All In Biotech

Drug Trial Radar · NCT04743505

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Phase I/II Study Exploring the Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Jan 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

27

Actual

Start

Jan 18, 2022

Primary completion

Jan 31, 2027

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Apollomics Inc.
First posted
Feb 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, patients with metastatic non-small cell lung cancer that is EGFR-mutated, who have received at least 8 and not more than 12 weeks of treatment with osimertinib without demonstrating disease progression, will receive APL-101 in combination with osimertinib until progression. Dosing of APL-101 will be escalated until the maximum tolerated dose is determined, at which point 10 additional patients will be enrolled at that dose in the expansion cohort.

Conditions

  • Metastatic Non Small Cell Lung Cancer

Interventions

  • APL-101Drug

    -Provided by Apollomics

  • OsimertinibDrug

    -Given standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Toxicity as measured by number of study treatment related adverse events (Phase I only)Time frame: Through 30 days after last dose of treatment (estimated to be 21 months)
  2. Toxicity as measured by number of study discontinuations due to treatment-related adverse events (Phase I only)Time frame: Through 30 days after last dose of treatment (estimated to be 21 months)
  3. Progression-free survival (PFS) (Phase II or received MTD only)Time frame: At 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University School of Medicine

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.